In thyroid cancer, the estrogen-related receptor γ (ERRγ, a nuclear receptor with high sequence identity to ERs) inverse agonist contributes to enhanced sensitivity towards radioiodine therapy, suggesting that it may be beneficial in restoring the unresponsiveness of poorly differentiated thyroid cancer cells to radioiodine therapy 87. This evidence concerns the gene ESRRG and thyroid gland carcinoma.